With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback